NewAmsterdam Pharma Company N.V. Warrant (NAMSW)
Stock · NASDAQ · Health Care
$8.82as of 10/16/2026
Price chart
Active signals
NAMSW Signal Track Record
How signals performed across all stocks →What NAMSW's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Bollinger Band Breakout | 28 | -1.3% | 46% | July 7, 2026 |
| Volume Spike | 22 | -2.4% | 36% | November 20, 2024 |
| Bollinger Band BreakdownActive now | 19 | +10.0% | 74% | September 3, 2026 |
| 200-Day Moving Average TouchActive now | 9 | +7.4% | 67% | March 9, 2026 |
| Any 20-session window (baseline) | +2.9% | 54% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About NAMSW
NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease. It is developing Obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 100
Fundamentals
- 1-day range
- $8.82$9.1
- Market cap
- $1.87B
- P/E (trailing)
- —
- P/E (forward)
- —
- EPS (trailing)
- —
- Dividend yield
- —
- Beta
- 7.27
- Avg. volume
- 1.2K
NewAmsterdam Pharma Company N.V. Warrant Competitors
Chosen by industry and closest market cap.
- NAMSWNewAmsterdam Pharma Company N.V. Warrant$9▼ 17.81%Market cap $1.87BP/E —$9.79$30.45
- ANIPANI Pharmaceuticals Inc.$72.29▲ 0.01%Market cap $1.86BP/E 15.16$69.58$97
- DMRADamora Therapeutics Inc. Ordinary Shares$18.44▼ 1.60%Market cap $1.84BP/E —$16.5$34.89
- AGIOAgios Pharmaceuticals Inc. Common Stock$31.32▼ 3.09%Market cap $1.91BP/E —$22.24$46
- NBTXNanobiotix S.A. American Depositary Shares$21.3▼ 4.18%Market cap $1.83BP/E —$13.1$47.66
- CMPSCOMPASS Pathways Plc American Depository Shares$10.75▼ 7.49%Market cap $1.83BP/E —$4.88$15.87
- OCULOcular Therapeutix Inc. Common Stock$6.87▼ 6.91%Market cap $1.92BP/E —$6.23$16.44
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| NAMSW NewAmsterdam Pharma Company N.V. Warrant | $1.87B | — | $9 | ▼ 17.81% | $9.79$30.45 |
| ANIP ANI Pharmaceuticals Inc. | $1.86B | 15.16 | $72.29 | ▲ 0.01% | $69.58$97 |
| DMRA Damora Therapeutics Inc. Ordinary Shares | $1.84B | — | $18.44 | ▼ 1.60% | $16.5$34.89 |
| AGIO Agios Pharmaceuticals Inc. Common Stock | $1.91B | — | $31.32 | ▼ 3.09% | $22.24$46 |
| NBTX Nanobiotix S.A. American Depositary Shares | $1.83B | — | $21.3 | ▼ 4.18% | $13.1$47.66 |
| CMPS COMPASS Pathways Plc American Depository Shares | $1.83B | — | $10.75 | ▼ 7.49% | $4.88$15.87 |
| OCUL Ocular Therapeutix Inc. Common Stock | $1.92B | — | $6.87 | ▼ 6.91% | $6.23$16.44 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Group 1 Automotive and 4 More Stocks See Action From Activist InvestorsYahoo · 10/2/2026
- NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Yahoo · 10/2/2026
- NewAmsterdam Pharma Doses First Participant in Phase 2b SPINOZA Trial Evaluating Obicetrapib in Preclinical Alzheimer’s DiseaseYahoo · 9/29/2026
- NewAmsterdam Pharma (NAMS) Wins EU Approvals. Can Cholesterol Pills Drive Royalties?Yahoo · 9/23/2026
- NewAmsterdam Pharma and Menarini Group Receive European Commission Approval for Ubeslo® (Obicetrapib Monotherapy) and Evlarco® (Obicetrapib Plus Ezetimibe Fixed-Dose Combination)Yahoo · 9/21/2026
- NewAmsterdam Pharma (NAMS) Stock Looks Above Fair Value After Its 139% RunYahoo · 9/20/2026
- Aclaris (ACRS) Soars 6.0%: Is Further Upside Left in the Stock?Yahoo · 9/15/2026
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 14, 2026
NewAmsterdam Pharma's SPINOZA Trial May Shift Alzheimer Strategy
NewAmsterdam Pharma is conducting a genotype‑targeted SPINOZA trial that could alter its long‑term Alzheimer approach. The study focuses on personalized treatment based on genetic markers. Results may influence the company's future research priorities.
NewAmsterdam Pharma's SPINOZA Trial May Shift Alzheimer Strategy. NewAmsterdam Pharma is conducting a genotype‑targeted SPINOZA trial that could alter its long‑term Alzheimer approach. The study focuses on personalized treatment based on genetic markers. Results may influence the company's future research priorities.